Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab

Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity

“…Ittiara et al. () reported bilateral exudative retinal detachment one year after an intravitreal bevacizumab injection in a 25‐week postmenstrual age premature infant with ROP. They concluded that regular follow‐up after intravitreal injections of bevacizumab for ROP should be continued until either the retina is fully vascularized or peripheral ablation is performed.…”

Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up

“…6,7,14 Demographic data on gestational age, birth weight and PMA at time of treatment and at last follow-up were collected.…”

“…Delayed recurrence of active ROP has been reported with high risk of development of RD following treatment with IVB. 2,6,7,14 The BEAT-ROP study recommended careful follow-up after IVB treatment until there is no active disease. The primary outcome in the BEAT-ROP trial was recurrence of neovascularization arising from retinal vessels and requiring retreatment by 54 weeks PMA.…”

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

“…98 Additionally, infants treated with bevacizumab or ranibizumab have been reported to have recurrence of ROP between 4 and 35 weeks after initial treatment. 95,96,99 Another small retrospective study that included 58 eyes noted that those infants requiring earlier bevacizumab treatment or had lower initial birth weights required significantly higher The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity rates of rescue treatment. 100 In the rat 50/10 OIR model, it was shown that inhibition of VEGF bioactivity using a neutralizing antibody led to later intravitreal neovascularization in part associated with activation of other angiogenic pathways.…”